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Driver Mutations and 
Prognosis in Resected 
Adenosquamous Lung 
Carcinomas
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in glandular component, bear very similar mutation 
profiles and clinicopathologic characteristics with 
poorly differentiated adenocarcinoma. However, high 
incidence of ALK or RET fusions and low rate of EGFR 
mutation were found in AdSqLCs with solid growth 
in glandular component. No significant differences 
were found in relapse-free survival or overall survival 
(OS) for AdSqLC patients with EGFR mutations 
versus KRAS, ALK, or wild-type whereas longer OS 
was found in patients with ALK rearrangements versus 
KRAS mutation. Worse OS were found in classical 
AdSqLC, poorly differentiated lung adenocarcinomas, 
and AdSqLCs with solid growth glandular component 
demonstrated versus moderate to well-differentiated 
adenocarcinomas. Further study on the growth pattern 
of glandular component in AdSqLCs could provide 
clinically useful insights. (p. 1255)
•	 small-Cell Carcinoma in 
the setting of Pulmonary 
Adenocarcinoma: new 
Insights in the era of 
Molecular Pathology
“Transformation” to small-cell lung carcinoma (SCLC) 
has been implicated in the mechanism of acquired 
resistance of lung adenocarcinoma to epidermal growth 
factor receptor (EGFR) tyrosine kinase inhibitors 
(TKIs). This study compared the clinical characteristics 
of patients and EGFR mutation status in SCLC 
associated synchronously or metachronously with 
lung adenocarcinoma, with or without TKI treatment. 
Formalin-fixed tissues of nine patients carrying lung 
adenocarcinoma and SCLC were sequenced for EGFR 
mutations. Six patients had metachronous occurrence 
of SCLC after adenocarcinoma, including two after 
TKI treatment; three had synchronous form. Four cases 
were of combined SCLC/adenocarcinoma. EGFR 
mutations in the adenocarcinoma component were 
found in seven cases whereas four SCLC components 
were EGFR mutated. The EGFR mutations identified 
in SCLC and adenocarcinoma components include 
exon 19 deletions and exon 21 mutations (E827, L833_
V834delinsFL, and L858R). This study suggests that 
EGFR mutations are associated with either synchronous 
or metachronous form of SCLC and adenocarcinoma, 
despite TKI treatment. Patients with EGFR mutant lung 
adenocarcinoma should be monitored closely because 
of the risk of developing combined SCLC or SCLC 
transformation. EGFR mutation analysis in patients 
diagnosed with SCLC and adenocarcinoma might reveal 
new information. (p. 1274)
In ThIs Issue
The authors reported the first comprehensive study on major oncogenic 
driver mutations in a large population of Chinese patients with 
adenosquamous lung carcinoma (AdSqLC). Of the 76 resected AdSqLCs, 
none harbored BRAF mutation whereas 56.6% had known kinase mutations, 
including EGFR (31.6%), KRAS (10.5%), AKT1 (2.6%), ERBB2 (1.3%), 
PIK3CA (1.3%), ALK fusions (5.3%), and KIF5B-RET fusions (4%). 
Classical AdSqLCs, with acinar, lepidic, micropapillary, or papillary growth 
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•	 stage-Adjusted Lung 
Cancer survival Does not 
Differ Between Low-
Income Blacks and Whites
A prospective study was conducted in a racially diverse 
and medically underserved population that included 
81,697 adults enrolled in the Southern Community 
Cohort Study across 11 states of the Southeastern 
United States from March 2002 to September 2009. 
Cancer mortality was evaluated among blacks and 
whites in the 501 incident non–small-cell lung 
cancer cases identified. In an average of 1.25 years of 
follow-up, death occurred in 75% of the cases. There 
were more blacks diagnosed with distant-stage disease 
than whites (57% versus 45%). However, there is no 
difference in stage-adjusted lung cancer mortality 
between these groups with similar low socioeconomic 
status. (p. 1248)
Network formed the basis of the recommendations, 
which were then reviewed and amended by specialists 
in medical and radiation oncology, radiology, lung 
disease, and population health. Eight randomized 
controlled trials and 13 single-arm studies of LDCT 
screening in high-risk individuals for lung cancer were 
conducted, including a large randomized trial that 
showed a significant decrease of lung cancer mortality 
using LDCT at 6 years versus chest radiograph. The 
recommendations generally follow the parameters of 
the National Lung Screening Study, with justification of 
deviations. In conclusion, the recommendations support 
LDCT screening of high-risk individuals for lung cancer, 
with strictly controlled implementation to achieve 
beneficial outcome. (p. 1232)
•	 screening high-Risk 
Populations for Lung 
Cancer: Guideline 
Recommendations
This is a practice guideline recommendation for screening high-risk 
populations for lung cancer with low-dose computed tomography (LDCT). 
It was developed based on the methods of Cancer Care Ontario’s Program in 
Evidence-Based Care. Evidence from a systematic review by the American 
Cancer Society, the American College of Chest Physicians, the American 
Society of Clinical Oncology, and the National Comprehensive Cancer 
•	 The effects of Chemotherapy 
on survival of elderly 
Patients with small-Cell 
Lung Cancer: Analysis of the 
seeR-Medicare Database
Caprario and colleagues conducted a retrospective analysis 
of factors influencing the administration of chemotherapy, 
and the impact of clinical and demographic variables on 
survival of elderly patients (age 65 years and older) with 
small-cell lung cancer (SCLC) between 1992 and 2001 
from the SEER-Medicare database. Of 10,428 patients, 
67.1% received chemotherapy, with the most common 
regimen being the combination of etoposide with cisplatin 
or carboplatin. The rest received radiation (39.1%), surgery 
(3.4%), and no treatment (21.8%). There are significantly 
fewer patients aged 85 years and older receiving 
chemotherapy versus those aged 65 to 69 years. All patients 
demonstrated a median survival of 7 months, of which 
a 6.5-month improvement was demonstrated by patients 
who underwent chemotherapy, even in patients aged over 
80 years. Improved survival was associated with female 
sex, black race, disease with limited stage, receiving any 
treatment, and lower comorbidity score. (p. 1281)
0.
00
0.
25
0.
50
0.
75
1.
00
0 12 24 36 48 60 72 84 96 108 120 132 144 156
Overall Survival in Months
Males, 7 months
Females, 8 months
Survival of SCLC Patients by Gender
p<0.001
0.
00
0.
25
0.
50
0.
75
1.
00
0 12 24 36 48 60 72 84 96 108 120 132 144 156
Overall Survival in Months
Ages 65 to 69, 9 months
Ages 70 to 74, 8 months
Ages 75 to 79, 6 months
Ages 80 to 84, 5 months
Ages 85 to 97, 3 months
Survival of SCLC Patients by Age
p<0.001
0.
00
0.
25
0.
50
0.
75
1.
00
0 12 24 36 48 60 72 84 96 108 120 132 144 156
Overall Survival in Months
W hite non-Hispanic, 7 months
W hite Hispanic, 7 months
Black, 7 months
Asian, 8 months
Native American, 7 months
Survival of SCLC Patients by Race
p=0.73
0.
00
0.
25
0.
50
0.
75
1.
00
0 12 24 36 48 60 72 84 96 108 120 132 144 156
Overall Survival in Months
No Treatment, 2 Months
Radiation Alone, 3 Months
Chemotherapy Alone, 9 Months
Radiation and Chemotherapy, 11 Months
Survival of SCLC Patients by Treatment
p<0.001
0.
00
0.
25
0.
50
0.
75
1.
00
0 12 24 36 48 60 72 84 96 108 120 132 144 156
Overall Survival in Months
No Chemotherapy, 2 Months
Carboplatin and Etoposide Alone, 11 Months
Cisplatin and Etoposide Alone, 11 Months
Other Combinations, 8 Months
Survival of SCLC Patients by Chemotherapy Type
p<0.001
0.
00
0.
25
0.
50
0.
75
1.
00
0 12 24 36 48 60 72 84 96 108 120 132 144 156
Overall Survival in Months
Limited, 10 months
Extensive, 5 months
Unstaged, 9 months
Survival of SCLC Patients by Stage
p < 0.001
1227Copyright © 2013 by the International Association for the Study of Lung Cancer
•	 Cost-effectiveness of 
Modified Fractionation 
Radiotherapy versus 
Conventional Radiotherapy 
for unresected non–
small-Cell Lung Cancer 
Patients
compared. The modified fractionations examined 
were two accelerated schemes (very accelerated 
radiotherapy and moderately accelerated radiotherapy) 
and two hyperfractionated schemes (identical or 
higher total treatment dose than CRT). The accelerated 
radiotherapy was the most cost-effective treatment: 
moderately accelerated radiotherapy had the highest 
probability of 43% (also highest quality-adjusted life 
years and net monetary benefits) followed by very 
accelerated radiotherapy (probability 31%), identical 
hyperfractionated radiotherapy (probability 24%), 
higher hyperfractionated radiotherapy (2%), and CRT 
(0%). The findings suggest that accelerated radiotherapy 
should be implemented as standard radiotherapy in 
unresected NSCLC patients who are not treated with 
concurrent chemoradiotherapy. (p. 1304)
ReseARCh WATCh
•	 Pleural effusion and 
Plasma samples versus 
Tumor Tissue for EGFR 
Mutation Analysis in 
Advanced nsCLC
and plasma provided high sensitivity (64%–82%) and specificity 
(80%–100%) in detecting EGFR mutation compared with tumor 
tissues. This supports MPE and plasma samples as valid surrogates 
when tissue is unavailable in the study population for EGFR status 
analysis. When comparing the different methods of mutation 
detection, amplification refractory mutation system was found to 
be most suitable for detecting mutation in tissues and MPE cell 
blocks. Despite the relatively lower sensitivity of mutant-specific 
immunohistochemistry, its high specificity and wide availability in 
hospitals suggest the method to be an alternative when DNA-based 
molecular analysis is not available.
Liu X, Lu Y, Zhu G, et al. The diagnostic accuracy of pleural 
effusion and plasma samples versus tumour tissue for detection 
of EGFR mutation in patients with advanced non–small cell lung 
cancer: comparison of methodologies. J Clin Pathol doi:10.1136/
jclinpath-2013–201728 (2013).
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Modified fractionation radiotherapy, which demonstrates survival benefits 
over the conventional fractionation radiotherapy (CRT) in non–small-cell 
lung cancer (NSCLC) patients, was assessed for its cost-effectiveness in 
this study for the curative treatment of unresected NSCLC patients. A 
probability Markov model was used, and aspects including Dutch health 
care costs, quality-adjusted life years, and net monetary benefits were 
This study aimed to validate malignant pleural effusion (MPE) 
and plasma as surrogate samples for the detection of epidermal 
growth factor receptor (EGFR) mutation when tumor tissue is not 
available in patients with advanced non–small-cell lung cancer. 
Matched tumor tissue and plasma samples from 86 patients 
with stage IIIB/IV adenocarcinoma/adenosquamous carcinoma, 
and matched MPE from a subgroup were analyzed for EGFR 
mutation using amplification refractory mutation system, Sanger 
sequencing and mutant-specific immunohistochemistry. MPE 
•	 TAILOR: Docetaxel More 
effective than erlotinib as 
second-Line Treatment for 
Advanced nsCLC with 
Wild-Type eGFR
of first-line chemotherapy, and performance status. The primary 
endpoint was overall survival. The findings revealed that docetaxel 
is more effective than erlotinib as second-line therapy for this 
study population: median overall survival was 8.2 months versus 
5.4 months and median progression-free survival was 2.9 months 
versus 2.4 months. The most common toxicities of grade 3–4 were 
low absolute neutrophil count (20% in docetaxel group versus 
none in erlotinib group), skin toxic effects (none versus 14%), and 
asthenia (10% versus 6%).
Garassino MC, Martelli O, Broggini M, et al. Erlotinib versus 
docetaxel as second-line treatment of patients with advanced non–
small-cell lung cancer and wild-type EGFR tumours (TAILOR): a 
randomised controlled trial. Lancet Oncol 2013;14:981–988.
This study evaluated the efficacy of erlotinib compared with a 
standard second-line chemotherapy in patients with advanced 
non–small-cell lung cancer harboring wild-type EGFR. This 
randomized controlled trial recruited patients with metastatic 
non–small-cell lung cancer, who had prior platinum-based 
chemotherapy harboring wild-type EGFR as determined by direct 
sequencing. Two hundred and twenty-two patients were randomly 
assigned to either erlotinib or docetaxel based on center, stage, type 
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•	 A novel, Fully Automated 
Immunochemistry Assay to 
Detect ALK-Positive Lung 
Adenocarcinoma
of staining results. Two cases with false-negative fluorescence in 
situ hybridization but strong ALK IHC-positive (Ventana and Cell 
Signaling Technology) and RT-polymerase chain reaction positive 
were found, and suggested the potential benefit from ALK inhibitor 
treatment in this subgroup of patients. Further studies are warranted 
to confirm the predictive value of ALK IHC in this setting. The 
authors concluded that the fully automated Ventana IHC is a 
reliable and rapid screening method in routine pathology laboratory 
to identify ALK rearrangement in patients with primary lung 
adenocarcinoma for ALK targeted therapy.
Ying J, Guo L, Qiu T, et al. Diagnostic value of a novel 
fully automated immunochemistry assay for detection of ALK 
rearrangement in primary lung adenocarcinoma. Ann Oncol, 
doi:10.1093/annonc/mdt295 (2013).
A novel, fully automated immunohistochemistry (IHC) assay 
(Ventana IHC) was assessed for its diagnostic value in the detection 
of anaplastic lymphoma kinase (ALK) rearrangement in comparison 
to a high-affinity Cell Signaling Technology IHC, fluorescence in 
situ hybridization, and RT-polymerase chain reaction. Retrospective 
analysis of 196 patients with ALK-positive lung adenocarcinoma 
demonstrated high sensitivity (100%) and specificity (98%) of 
Ventana IHC in screening this population. A binary scoring system 
(ALK-positive or -negative) was used by this assay in assessment 
neWs In BRIeF
•	 u.s. Preventive services Task 
Force (usPsTF) Backs LDCT 
screening in high-Risk 
Groups for Lung Cancer
The USPSTF issued a new recommendation to use low-
dose computed tomography annually in screening for 
lung cancer in current or former smokers aged 55 to 79 
years with a 30 pack-year smoking history, or who have 
quit smoking in the past 15 years. The recommendation 
for lung cancer screening is given grade B, indicating 
moderate certainty on benefit from screening. This grade 
B recommendation from the task force will lead to service 
coverage by medical insurance under the Affordable Care 
Act. The agency also stressed that lung cancer screening 
should not be viewed as a substitute for quitting smoking 
in spite of its benefits.
Photo credit: Pulmonary Pathology http://www.flickr.
com/photos/pulmonary_pathology/6327961286/in/
photostream/
•	 Cancer Research uK 
Launched new Research 
to Revolutionize 
understanding of Lung 
Cancer
the support of £14 million. This pioneering project 
will gather 65 lung cancer researchers in the United 
Kingdom, including oncologists, pathologists, laboratory 
researchers, and technicians from hospitals, universities, 
and research institutes. Biopsy specimens from different 
parts of tumors will be taken and analyzed for a more 
comprehensive genetic profile. Blood tests of circulating 
tumor DNA will be performed so genetic changes in and 
among patients in response to drug treatments and the 
ultimate effect on the patients’ survival can be evaluated 
and compared. This revolutionary approach will provide 
important insights for understanding lung cancer, which 
will improve personalized treatments.
Photo source: http://www.cancer.gov
The Tracking Cancer Evolution through Therapy study launched by Cancer 
Research UK will recruit 850 lung cancer patients from across the United 
Kingdom and perform real-time tracking to determine how lung cancers 
mutate, adapt, and acquire resistance to therapies, over 9 years with 
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•	 Trends Overview: 
european Cancer Mortality 
since 1980
sites in 34 European countries. The findings, published in 
Annals of Oncology, showed a steady decline in cancer 
mortality in general across Europe, by 1.6% per year 
(2002–2009) in men and 1% per year (1993–2009) in 
women. However, the rates have been increasing for lung 
cancer in women, and pancreatic and soft tissue sarcomas 
in both sexes. The persistent rise in lung cancer mortality 
in women from most European countries reflects the late 
spread of tobacco smoking among them compared with 
men. The drop in smoking prevalence a few decades 
earlier in the United Kingdom and The Netherlands 
resulted in a plateau in the lung cancer epidemic although 
the epidemic is still rising in western and central/eastern 
Europe. The authors predict the increase of lung cancer 
mortality in women to reach 14.0/100,000 in 2015.
The authors analyzed data from the World Health Organization from 2005 
to 2009 to determine the trends of cancer mortality since 1980 for 25 cancer 
